Hawryluk P. Kent 4

What Happened
P. Kent Hawryluk, President & CEO and a director of MBX Biosciences (MBX), acquired 18,500 shares in open-market purchases on March 13, 2026. The reported weighted-average price was $28.41 per share, for a total reported transaction value of $525,663. This was a purchase (transaction code P), i.e., the insider added to his holdings.

Key Details

• Transaction date: 2026-03-13; Form 4 filed: 2026-03-16 (timely filing).
• Price: weighted average $28.41; trades occurred at prices ranging $28.28–$28.48 (see footnote).
• Shares acquired: 18,500; total value ≈ $525,663.
• Shares held after transaction: not specified in the provided extract.
• Footnotes: F1 notes the weighted-average price and that breakdown by price is available on request; F2 indicates some shares are held by the P. Kent Hawryluk Revocable Trust (he is trustee and disclaims beneficial ownership except to the extent of any pecuniary interest).

Context
This was a direct open-market purchase, which shows the insider bought additional stock; Form 4 rules require filing within two business days after the transaction and this filing appears timely. The footnote about the trust clarifies certain holdings may be held in trust rather than directly in the insider’s name.